Cyclacel Pharmaceuticals to Participate in March Investor Conferences

BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences.

Oppenheimer 33rd Annual Healthcare Conference:

Location: Virtual
Format: Fireside chat and one-on-one meetings
Date: March 13-15, 2023
Fireside chat: March 13, 10:00am ET
Presenter: Spiro Rombotis
Webcast: Link

35th Annual Roth Conference:

Location: Dana Point, CA
Format: Fireside chat and one-on-one meetings
Date: March 12-14, 2023
Fireside chat: March 13, 3:00pm PT
Presenter: Paul McBarron
Webcast: Link

About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit


Company: Paul McBarron, (908) 517-7330,
Investor Relations: Irina Koffler, LifeSci Advisors, LLC, (646) 970-4681,

© Copyright 2023 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.

Primary Logo

Back to news